Sangamo Therapeutics (SGMO) Stock Price, News & Analysis

Company Overview

Sangamo Therapeutics, Inc. is a clinical-stage biotechnology company headquartered in Brisbane, California, that specializes in the development of genomic therapies based on its proprietary zinc finger nuclease (ZFN) technology. Founded in 1995, Sangamo pioneered ZFN-based genome editing to precisely alter DNA sequences for the treatment of serious genetic and rare diseases. The company’s platform encompasses in vivo genome editing, ex vivo cell therapy, and genome regulation approaches, with a focus on durable therapeutic effects through permanent genetic modification or sustained gene expression control.

Through its genome editing programs, Sangamo is advancing multiple product candidates into clinical trials for conditions such as hemophilia A and B, mucopolysaccharidosis types I and II, and lysosomal storage disorders. The company’s ex vivo programs leverage ZFN technology to engineer patient-derived cells for applications in immuno-oncology and regenerative medicine. Sangamo also develops gene regulation therapeutics using zinc finger transcription factors designed to upregulate or silence disease-related genes without altering the underlying DNA sequence.

Over the years, Sangamo has formed strategic partnerships with leading pharmaceutical and biotechnology firms to expand its research capabilities and accelerate the development of its pipeline. Collaborators have included major global players in hemophilia, metabolic disorders, and neuroscience, supporting clinical development, manufacturing scale-up, and regulatory filings. Sangamo maintains research operations and manufacturing facilities in the San Francisco Bay Area and collaborates with academic and industry partners worldwide.

Sangamo is led by President and Chief Executive Officer Sandy Macrae, under whose guidance the company has continued to innovate in genome engineering and advance its most promising candidates through regulatory milestones and clinical proof-of-concept studies. With a commitment to addressing unmet medical needs, Sangamo Therapeutics leverages its ZFN platform to develop next-generation therapies aimed at transforming the treatment landscape for patients with genetic and rare diseases.

Key Stats

• Today's Range: $0.49 to $0.52
• 50-Day Range: $0.44 to $0.60
• 52-Week Range: $0.41 to $3.18
• Volume: 3.67 million shs
• Average Volume: 4.05 million shs
• Market Capitalization: $150.95 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $4.50
• Consensus Rating: Moderate Buy

Sangamo Therapeutics Stock Analysis - MarketRank™

Sangamo Therapeutics scored higher than 54% of companies evaluated by MarketBeat, and ranked 598th out of 960 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Sangamo Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on 4 buy ratings, 2 hold ratings, and no sell ratings.

Upside Potential

Sangamo Therapeutics has a consensus price target of $4.50, representing about 799.5% upside from its current price of $0.50.

Amount of Analyst Coverage

Sangamo Therapeutics has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Sangamo Therapeutics are expected to grow in the coming year, from ($0.46) to ($0.26) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Sangamo Therapeutics is -1.73, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Sangamo Therapeutics is -1.73, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Sangamo Therapeutics has a P/B Ratio of 4.55. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 4.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

5.18% of the float of Sangamo Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Sangamo Therapeutics has a short interest ratio ("days to cover") of 2.6, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Sangamo Therapeutics has recently decreased by 6.14%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Sangamo Therapeutics does not currently pay a dividend.

Dividend Growth

Sangamo Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

5.18% of the float of Sangamo Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Sangamo Therapeutics has a short interest ratio ("days to cover") of 2.6, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Sangamo Therapeutics has recently decreased by 6.14%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 2.9 / 5
• News Sentiment: 1.25

News Sentiment

Sangamo Therapeutics has a news sentiment score of 1.25. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.94 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 3 news articles for Sangamo Therapeutics this week, compared to 3 articles on an average week.

Search Interest

Only 7 people have searched for SGMO on MarketBeat in the last 30 days. This is a decrease of -56% compared to the previous 30 days.

MarketBeat Follows

6 people have added Sangamo Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 20% compared to the previous 30 days.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Sangamo Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 4.10% of the stock of Sangamo Therapeutics is held by insiders.

Percentage Held by Institutions

56.93% of the stock of Sangamo Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

SGMO Stock Analysis - Frequently Asked Questions

How have SGMO shares performed this year?

Sangamo Therapeutics' stock was trading at $1.02 at the start of the year. Since then, SGMO stock has decreased by 51.0% and is now trading at $0.5003.

How were Sangamo Therapeutics' earnings last quarter?

Sangamo Therapeutics, Inc. (NASDAQ:SGMO) posted its quarterly earnings data on Thursday, August, 7th. The biopharmaceutical company reported ($0.08) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.07) by $0.01. The biopharmaceutical company earned $18.31 million during the quarter, compared to the consensus estimate of $31.68 million. Sangamo Therapeutics had a negative trailing twelve-month return on equity of 293.05% and a negative net margin of 77.48%.
Read the conference call transcript.

Who are Sangamo Therapeutics' major shareholders?

Top institutional investors of Sangamo Therapeutics include Wasatch Advisors LP (3.47%), Geode Capital Management LLC (1.00%), Invesco Ltd. (0.29%) and Golden State Equity Partners (0.17%).
View institutional ownership trends.

How do I buy shares of Sangamo Therapeutics?

Shares of SGMO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Sangamo Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Sangamo Therapeutics investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Meta Platforms (META), Intel (INTC), MSP Recovery (LIFW), abrdn Asia-Pacific Income Fund (FAX) and Tesla (TSLA).

Company Calendar

• Last Earnings: 8/07/2025
• Today: 9/16/2025
• Next Earnings (Estimated): 11/11/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:SGMO
• CIK: 1001233
• Web: www.sangamo.com
• Phone: (510) 970-6000
• Fax: 510-236-8951
• Employees: 480
• Year Founded: 1995

Price Target and Rating

• Average Price Target for Sangamo Therapeutics: $4.50
• High Price Target: $10.00
• Low Price Target: $2.00
• Potential Upside/Downside: +799.5%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.67
• Research Coverage: 6 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.29)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$97.94 million
• Net Margins: -77.48%
• Pretax Margin: -77.72%
• Return on Equity: -293.05%
• Return on Assets: -63.85%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 1.05
• Quick Ratio: 1.05

Sales & Book Value

• Annual Sales: $81.71 million
• Price / Sales: 1.85
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.11 per share
• Price / Book: 4.55

Miscellaneous

• Outstanding Shares: 301,709,000
• Free Float: 289,339,000
• Market Cap: $150.95 million
• Optionable: Optionable
• Beta: 1.20